6505--Ustekinumab Pens/Syringes or Biosimilar

The Department of Veterans Affairs National Acquisition Center is soliciting offers for a pharmaceutical prime vendor contract to supply Ustekinumab in three dosage strengths (5mg/ml, 45mg/0.5ml, and 90mg/ml) in pens or syringes, or FDA-licensed biosimilar alternatives. The contract will support distribution through the VA and DoD Pharmaceutical Prime Vendor Programs to multiple federal agencies including the Veterans Health Administration, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. Offerors must provide pricing for all three line items across the base year and four one-year option periods and include a mandatory 0.5% Cost Recovery Fee with a unique 11-digit NDC number for each product. The solicitation does not specify explicit evaluation criteria beyond the pricing and product requirements. The deadline for submission of offers is February 10, 2026 at 2:30 PM Central Standard Time, with this deadline having been extended twice from the original January 26, 2026 date; offerors must acknowledge receipt of all amendments to avoid rejection.

This solicitation contains no set-aside designations and is open to unrestricted competition while supporting small business participation. No incumbent contractors are identified in the solicitation documents. The estimated annual usage across all participating agencies ranges from 2,917 to 45,763 units per line item, reflecting substantial federal pharmaceutical procurement needs, though specific contract award values are not disclosed in the available documentation. The contract structure comprises one base year followed by four one-year option periods, providing potential for five years of supply. Distribution will be managed through existing Prime Vendor contractors such as McKesson Corporation and Cardinal Health, with products delivered to multiple federal facilities and agencies across the United States.